Head-to-head evidence
ABP 692 vs BCD-132
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Sclerosis
Shared mechanism: CD20 · full Multiple Sclerosis pipeline
ABP 692
Developed by Amgen
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: April 2027 · NCT06700343 (registry estimate)
BCD-132
Developed by Biocad
NCT05385744 · Phase 3 · completed
Randomized, double-blind, active-controlled Phase 3 trial (n=480) showing superior relapse reduction vs teriflunomide (PMID 38676683).
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ABP 692's landscape · BCD-132's landscape